Supplementary Fig. 3. Reproducibility of IMmunotherapy Against Gastric Cancer (IMAGiC) model using a quantitative real-time polymerase chain reaction platform. (A) Correlations between IMAGiC model, Response Evaluation Criteria in Solid Tumors (RECIST) group \((r^2=0.83)\), Epstein-Barr virus (EBV; \(r^2=0.49\)), and microsatellite unstable (MSI; \(r^2=0.66\)). (B, C, D) Boxplot comparing IMAGiC scores between RECIST groups \((P=0.0051)\), MSI subtypes \((P=0.0028)\), and EBV subtypes \((P=0.081)\). PD-L1, programmed death ligand 1; CPS, combined positive score; TMB, tumor mutational burden; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.